KR101551681B1 - 변형된 히알루론산 폴리머 조성물 및 관련방법 - Google Patents

변형된 히알루론산 폴리머 조성물 및 관련방법 Download PDF

Info

Publication number
KR101551681B1
KR101551681B1 KR1020127005345A KR20127005345A KR101551681B1 KR 101551681 B1 KR101551681 B1 KR 101551681B1 KR 1020127005345 A KR1020127005345 A KR 1020127005345A KR 20127005345 A KR20127005345 A KR 20127005345A KR 101551681 B1 KR101551681 B1 KR 101551681B1
Authority
KR
South Korea
Prior art keywords
hydrogel
hyaluronic acid
composition
solution
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127005345A
Other languages
English (en)
Korean (ko)
Other versions
KR20120052371A (ko
Inventor
핑그렌 헤
데이비드 엠. 그라벳
조지 와이. 다닐로프
Original Assignee
카르빌란 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42932126&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101551681(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 카르빌란 테라퓨틱스, 인코포레이티드 filed Critical 카르빌란 테라퓨틱스, 인코포레이티드
Publication of KR20120052371A publication Critical patent/KR20120052371A/ko
Application granted granted Critical
Publication of KR101551681B1 publication Critical patent/KR101551681B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR1020127005345A 2009-07-30 2010-07-23 변형된 히알루론산 폴리머 조성물 및 관련방법 Expired - Fee Related KR101551681B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23007409P 2009-07-30 2009-07-30
US61/230,074 2009-07-30
US31195310P 2010-03-09 2010-03-09
US61/311,953 2010-03-09

Publications (2)

Publication Number Publication Date
KR20120052371A KR20120052371A (ko) 2012-05-23
KR101551681B1 true KR101551681B1 (ko) 2015-09-09

Family

ID=42932126

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005345A Expired - Fee Related KR101551681B1 (ko) 2009-07-30 2010-07-23 변형된 히알루론산 폴리머 조성물 및 관련방법

Country Status (15)

Country Link
US (5) US7829118B1 (cg-RX-API-DMAC7.html)
EP (1) EP2459239A1 (cg-RX-API-DMAC7.html)
JP (1) JP5683587B2 (cg-RX-API-DMAC7.html)
KR (1) KR101551681B1 (cg-RX-API-DMAC7.html)
CN (1) CN102573941B (cg-RX-API-DMAC7.html)
AU (1) AU2010276574B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012002117A2 (cg-RX-API-DMAC7.html)
CA (1) CA2769470A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000243A1 (cg-RX-API-DMAC7.html)
IL (1) IL217750B (cg-RX-API-DMAC7.html)
MX (1) MX2012001204A (cg-RX-API-DMAC7.html)
RU (1) RU2539395C2 (cg-RX-API-DMAC7.html)
SG (1) SG178146A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011014432A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200727B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160067887A (ko) * 2013-10-08 2016-06-14 큐피가부시키가이샤 카르복시메틸기 함유 수식 히알루론산 및/또는 그 염 및/또는 그 제조 방법
US11602539B2 (en) 2016-09-06 2023-03-14 Bmi Korea Co., Ltd Hemostatic composition comprising cross-linked hyaluronic acid derivative matrix
KR20230059162A (ko) * 2021-10-25 2023-05-03 바이오플러스 주식회사 가교 히알루론산을 포함하는 가슴 보형물 및 이의 제조방법

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012002117A2 (pt) 2009-07-30 2019-09-24 Carbylan Biosurgery Inc composições poliméricas modificadas de ácido hialurônico e métodos relacionados.
CZ2009836A3 (cs) 2009-12-11 2011-06-22 Contipro C A.S. Derivát kyseliny hyaluronové oxidovaný v poloze 6 glukosaminové cásti polysacharidu selektivne na aldehyd, zpusob jeho prípravy a zpusob jeho modifikace
CZ302503B6 (cs) 2009-12-11 2011-06-22 Contipro C A.S. Zpusob prípravy derivátu kyseliny hyaluronové oxidovaného v poloze 6 glukosaminové cásti polysacharidu selektivne na aldehyd a zpusob jeho modifikace
CA2805008C (en) * 2010-07-12 2015-05-12 Shin Poong Pharmaceutical Co., Ltd. Filler composition for tissue augmentation comprising a hydrogel of hyaluronic acid cross-linked with alkylene diamine
FR2968306B1 (fr) * 2010-12-06 2014-02-28 Teoxane Procede de preparation d'un gel reticule
US20120142628A1 (en) * 2010-12-07 2012-06-07 Allergan, Inc. Methods for treating crepitus
GB201101429D0 (en) * 2011-01-27 2011-03-16 Biocompatibles Uk Ltd Drug delivery system
DK2699274T3 (en) * 2011-04-20 2015-06-15 Carbylan Therapeutics Inc In situ gelling formations
CZ304072B6 (cs) * 2011-04-26 2013-09-25 Contipro Biotech S.R.O. Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití
CA2838059C (en) * 2011-06-03 2020-08-25 Maguire Abbey, Llc Method, composition, and articles for improving joint lubrication
WO2012171335A1 (en) * 2011-06-16 2012-12-20 The Hong Kong University Of Science And Technology Multi-vinylsulfone containing molecule
TWI561535B (en) 2011-10-06 2016-12-11 Bvw Holding Ag Copolymers of hydrophobic and hydrophilic segments that reduce protein adsorption
US20130108550A1 (en) 2011-10-26 2013-05-02 Abbott Cardiovasculr Systems, Inc. Bioabsorbable Co-Filler for Cerebrovascular Aneurysms
WO2013078770A1 (en) * 2011-12-02 2013-06-06 The Hong Kong University Of Science And Technology Injectable gelling material
CZ303879B6 (cs) 2012-02-28 2013-06-05 Contipro Biotech S.R.O. Deriváty na bázi kyseliny hyaluronové schopné tvorit hydrogely, zpusob jejich prípravy, hydrogely na bázi techto derivátu, zpusob jejich prípravy a pouzití
CZ304512B6 (cs) 2012-08-08 2014-06-11 Contipro Biotech S.R.O. Derivát kyseliny hyaluronové, způsob jeho přípravy, způsob jeho modifikace a použití
CZ304654B6 (cs) 2012-11-27 2014-08-20 Contipro Biotech S.R.O. Nanomicelární kompozice na bázi C6-C18-acylovaného hyaluronanu, způsob přípravy C6-C18-acylovaného hyaluronanu, způsob přípravy nanomicelární kompozice a stabilizované nanomicelární kompozice a použití
HK1214618A1 (zh) 2013-01-11 2016-07-29 Carbylan Therapeutics, Inc. 含有透明質酸的穩定化組合物
JP6215354B2 (ja) * 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ, インコーポレイテッド 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
JP6781220B2 (ja) * 2013-02-04 2020-11-04 ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated 基板用コーティング
RU2698315C2 (ru) * 2013-02-04 2019-08-26 В.Л. Гор Энд Ассошиейтс, Инк. Покрытие для подложки
US9511119B2 (en) * 2013-03-15 2016-12-06 NuTech Spine, Inc. Preparations containing hepatocyte growth factor and hyaluronic acid and methods of making and using same
US9844597B2 (en) 2013-04-18 2017-12-19 The Hong Kong University Of Science And Technology Biocompatible in situ hydrogel
RU2640865C2 (ru) * 2013-06-28 2018-01-12 Гальдерма С.А. Способ производства формованного продукта из поперечно-сшитой гиалуроновой кислоты
WO2015053282A1 (ja) * 2013-10-08 2015-04-16 キユーピー株式会社 カルボキシメチル基含有修飾ヒアルロン酸および/またはその塩の架橋物およびその製造方法
WO2015053281A1 (ja) * 2013-10-08 2015-04-16 キユーピー株式会社 カルボキシメチル基含有修飾ヒアルロン酸および/またはその塩の架橋物およびその製造方法
WO2015134906A1 (en) * 2014-03-07 2015-09-11 Endologix, Inc. Forming hydrogels and materials therefor
US9895394B2 (en) * 2014-03-10 2018-02-20 Kai-shun Christopher LEUNG Induction of chronic elevation of intraocular pressure with vinysulfonated hyaluronic acid (HA-VS) and thiolated hyaluronic acid (HA-SH)hydrogel
CZ2014150A3 (cs) 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Konjugáty oligomeru kyseliny hyaluronové nebo její soli, způsob jejich přípravy a použití
CZ2014451A3 (cs) 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
KR20170070008A (ko) 2014-08-15 2017-06-21 더 존스 홉킨스 유니버시티 조직 복원용 복합 재료
CZ309295B6 (cs) 2015-03-09 2022-08-10 Contipro A.S. Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití
CZ2015398A3 (cs) 2015-06-15 2017-02-08 Contipro A.S. Způsob síťování polysacharidů s využitím fotolabilních chránicích skupin
CZ306662B6 (cs) 2015-06-26 2017-04-26 Contipro A.S. Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití
EP3320028A1 (en) * 2015-09-01 2018-05-16 Merz Pharma GmbH & Co. KGaA Method of making a cross-linked polymer gel and device for performing the method
WO2017042301A1 (en) * 2015-09-09 2017-03-16 ETH Zürich Injectable macroporous hydrogels
CN108697804B (zh) * 2015-10-05 2022-11-15 德克萨斯州立大学董事会 用于软骨损伤的检测和治疗的微米和纳米装置
CN105606602A (zh) * 2015-12-22 2016-05-25 上海景峰制药有限公司 一种测定交联透明质酸钠凝胶中二巯基聚乙二醇残留的方法
TWI727014B (zh) * 2016-03-24 2021-05-11 德商梅茲製藥有限兩合公司 修飾透明質酸與其製造方法及其用途
CZ308106B6 (cs) 2016-06-27 2020-01-08 Contipro A.S. Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití
EP4253956A3 (en) * 2016-10-14 2023-12-06 Wake Forest University Health Sciences Multi-organ "body on a chip" apparatus utilizing a common media
WO2018136205A1 (en) * 2016-12-29 2018-07-26 Tempo Therapeutics, Inc. Methods and systems for treating a site of a medical implant
BR112019017795B1 (pt) 2017-02-28 2022-12-06 Cg Bio Co., Ltd. Composição para injeção dérmica
EP3590546B1 (en) * 2017-02-28 2024-08-21 CG Bio Co., Ltd. Composition for skin injection
WO2018159982A1 (ko) * 2017-02-28 2018-09-07 (주)시지바이오 피부 주입용 조성물
US20180250225A1 (en) * 2017-03-01 2018-09-06 Church & Dwight Co., Inc. Gummy composition with improved stability
EP3600442A1 (en) * 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
US11419941B2 (en) 2017-05-30 2022-08-23 Brenda K. Mann Vaginal hydrogel
JP7854781B2 (ja) * 2017-09-01 2026-05-07 ピーエムアイディージー・エルエルシー 官能基化および架橋ポリマー
US12029753B2 (en) 2017-09-19 2024-07-09 The Hong Kong University Of Science And Technology Biocompatible material and methods for making and using thereof
US20190240335A1 (en) * 2018-02-07 2019-08-08 Promedon S.A. Biocompatible Hydrogel Compositions
US10959945B2 (en) 2018-03-21 2021-03-30 Marina Lee Gerton Vaginal hydrogel for delivery of therapeutics
EP3790602A1 (en) 2018-05-09 2021-03-17 The Johns Hopkins University Nanofiber-hydrogel composites for cell and tissue delivery
ES3060255T3 (en) 2018-05-09 2026-03-25 Univ Johns Hopkins Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration
CN112702992A (zh) * 2018-07-20 2021-04-23 香港科技大学 用于靶试剂的受控释放的组合物和方法
CN109045354B (zh) * 2018-07-26 2020-12-08 华中科技大学 一种用于骨-软骨综合修复的原位成型可注射水凝胶
EP3852725A4 (en) * 2018-09-20 2022-08-03 The Hong Kong University of Science and Technology EYE DROP COMPOSITIONS
CN109223708B (zh) * 2018-10-24 2021-07-20 上海景峰制药有限公司 一种交联玻璃酸钠的抗肿瘤药物组合物及其制备方法和应用
EP3956367A1 (en) * 2019-04-19 2022-02-23 Jointherapeutics S.r.l. Crosslinked polymer of functionalized hyaluronic acid and its use in the treatment of inflammatory states
KR102176486B1 (ko) * 2019-06-14 2020-11-10 동국대학교 산학협력단 히알루론산 기반의 안과용 약물전달체의 제조방법
CN111187429B (zh) * 2019-06-18 2020-08-14 吾奇生物医疗科技(镇江)有限公司 双交联胶原水凝胶材料、其制备方法与应用
WO2020264392A1 (en) * 2019-06-26 2020-12-30 Lacerta Technologies Inc. Cross-linked hyaluronic acid hydrogels comprising proteins
CN110204746B (zh) * 2019-06-28 2022-03-08 浙江科技学院 一种交联透明质酸钠凝胶的制备方法
EP4090317A4 (en) * 2020-01-16 2024-02-21 The Hong Kong University of Science and Technology COMPOSITIONS AND METHODS FOR CONTROLLED RELEASE OF A TARGET AGENT
JP2023522079A (ja) * 2020-04-17 2023-05-26 ブレンダン パトリック パーセル ヒアルロン酸組成物の制御放出
US20230173074A1 (en) * 2020-04-23 2023-06-08 Pleryon Therapeutics (Shenzhen) Limited Biocompatible material and methods for making and using the same
WO2022120097A1 (en) * 2020-12-03 2022-06-09 Pmidg, Llc Functionalized and crosslinked polymers
CN114276563B (zh) * 2020-12-14 2023-02-24 南京工业大学 医用水凝胶的制备方法、水凝胶及敷料
WO2022165416A1 (en) * 2021-02-01 2022-08-04 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for making and using hybrid network hydrogels
DE102021212812A1 (de) * 2021-11-15 2023-05-17 Bauerfeind Ag Entzündungshemmendes viskosupplementierendes Mittel enthaltend Hyaluronsäure
ES2997963T3 (en) * 2021-11-16 2025-02-18 Pompadour Iberica S A A beverage composition with controlled effervescence for infusion in a cold liquid
CN116919983A (zh) * 2022-04-07 2023-10-24 北京瑞熙天成生物科技有限公司 一种用于治疗关节炎的基于官能化透明质酸或其钠盐的药物组合及其应用
CN116919982A (zh) * 2022-04-07 2023-10-24 北京瑞熙天成生物科技有限公司 一种用于治疗关节炎的药物组合物及其应用
CN115364044B (zh) * 2022-06-17 2024-07-09 浙江大学医学院附属第一医院 一种药物组合物及其制备方法和用途
WO2024030437A1 (en) * 2022-08-01 2024-02-08 Pmidg, Llc Functionalized and crosslinked polymer methods and compositions
KR20260009801A (ko) * 2023-02-15 2026-01-20 라이프스프라웃, 인크. 콜라겐-히드로겔 복합체
CN121013705A (zh) * 2023-02-15 2025-11-25 生命萌芽公司 改性的交联聚合物
FI20245016A1 (en) * 2024-01-11 2025-07-12 Fysioline Oy INJECTABLE COMPOSITION FOR CONTROLLED MEDICINE ADMINISTRATION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939086A1 (en) 1998-02-27 1999-09-01 Stichting Hippomedics Process for producing crosslinked hyaluronic acid
WO2001060868A1 (en) 2000-02-14 2001-08-23 Genzyme Corporation Single phase gels for the prevention of adhesions
WO2005066215A1 (en) 2003-12-30 2005-07-21 Genzyme Corporation Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use
WO2006056204A1 (en) 2004-11-24 2006-06-01 Novozymes Biopolymer A/S Method of cross-linking hyaluronic acid with divinylsulfone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5356883A (en) 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
DK130991D0 (da) 1991-07-04 1991-07-04 Immunodex K S Polymere konjugater
WO1997022371A1 (en) 1995-12-18 1997-06-26 Collagen Corporation Crosslinked polymer compositions and methods for their use
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6056970A (en) 1998-05-07 2000-05-02 Genzyme Corporation Compositions comprising hemostatic compounds and bioabsorbable polymers
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
WO2002009792A1 (en) * 2000-07-28 2002-02-07 Anika Therapeutics, Inc. Bioabsorbable composites of derivatized hyaluronic acid
WO2002068383A2 (en) * 2001-02-22 2002-09-06 Anika Therapeutics, Inc. Thiol-modified hyaluronan
WO2003096015A1 (en) 2002-05-08 2003-11-20 Matsushita Electric Industrial Co., Ltd. Biomolecular substrate, method of testing or diagnosis with use thereof and apparatus therefor
US7034127B2 (en) * 2002-07-02 2006-04-25 Genzyme Corporation Hydrophilic biopolymer-drug conjugates, their preparation and use
US6802377B2 (en) 2002-08-28 2004-10-12 Mark S. Foltz Hammer mounting apparatus
WO2004046200A1 (ja) 2002-11-21 2004-06-03 Chugai Seiyaku Kabushiki Kaisha 薬物徐放担体
US20050056608A1 (en) 2003-09-15 2005-03-17 Nesin Milton Scott Bottle insert for storing and dispensing baby formula
US20050282747A1 (en) * 2003-10-01 2005-12-22 The Research Foundation Of State University Of New York At Stony Brook Methods and compositions for wound healing
WO2005054301A1 (ja) 2003-11-14 2005-06-16 Chugai Seiyaku Kabushiki Kaisha 架橋多糖微粒子およびその製造方法
EP1694712A1 (en) 2003-12-04 2006-08-30 University of Utah Research Foundation Modified macromolecules and methods of making and using thereof
KR20060130606A (ko) 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
US8524213B2 (en) 2003-12-30 2013-09-03 Genzyme Corporation Polymeric materials, their preparation and use
WO2006028110A1 (ja) 2004-09-07 2006-03-16 Chugai Seiyaku Kabushiki Kaisha 水溶性ヒアルロン酸修飾物の製造方法
JP4875988B2 (ja) * 2004-11-15 2012-02-15 株式会社 資生堂 架橋ヒアルロン酸ゲルの製造方法
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
EP1994062B1 (en) 2006-03-02 2009-07-15 Novozymes Biopolymer A/S Aryl/alkyl vinyl sulfone hyaluronic acid derivatives
EP1871038B1 (en) 2006-06-23 2010-06-02 Nippon Office Automation Co., Ltd. Network protocol and session analyser
WO2008008857A2 (en) 2006-07-11 2008-01-17 University Of Utah Research Foundation Thiolated macromolecules and methods of making and using thereof
TWI436793B (zh) 2006-08-02 2014-05-11 巴克斯特國際公司 快速作用之乾密封膠及其使用和製造方法
CN101200504B (zh) 2006-12-11 2010-05-12 上海百瑞吉生物医药有限公司 高分子巯基化改性衍生物及其交联材料
US20110077737A1 (en) 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
BR112012002117A2 (pt) 2009-07-30 2019-09-24 Carbylan Biosurgery Inc composições poliméricas modificadas de ácido hialurônico e métodos relacionados.
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939086A1 (en) 1998-02-27 1999-09-01 Stichting Hippomedics Process for producing crosslinked hyaluronic acid
WO2001060868A1 (en) 2000-02-14 2001-08-23 Genzyme Corporation Single phase gels for the prevention of adhesions
WO2005066215A1 (en) 2003-12-30 2005-07-21 Genzyme Corporation Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use
WO2006056204A1 (en) 2004-11-24 2006-06-01 Novozymes Biopolymer A/S Method of cross-linking hyaluronic acid with divinylsulfone

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160067887A (ko) * 2013-10-08 2016-06-14 큐피가부시키가이샤 카르복시메틸기 함유 수식 히알루론산 및/또는 그 염 및/또는 그 제조 방법
KR102268945B1 (ko) 2013-10-08 2021-06-23 큐피가부시키가이샤 카르복시메틸기 함유 수식 히알루론산 및/또는 그 염 및/또는 그 제조 방법
US11602539B2 (en) 2016-09-06 2023-03-14 Bmi Korea Co., Ltd Hemostatic composition comprising cross-linked hyaluronic acid derivative matrix
KR20230059162A (ko) * 2021-10-25 2023-05-03 바이오플러스 주식회사 가교 히알루론산을 포함하는 가슴 보형물 및 이의 제조방법
KR102888000B1 (ko) 2021-10-25 2025-11-24 바이오플러스 주식회사 가교 히알루론산을 포함하는 가슴 보형물 및 이의 제조방법

Also Published As

Publication number Publication date
US20160193342A1 (en) 2016-07-07
IL217750A0 (en) 2012-03-29
SG178146A1 (en) 2012-03-29
WO2011014432A1 (en) 2011-02-03
JP2013501091A (ja) 2013-01-10
US20140328926A1 (en) 2014-11-06
US9192678B2 (en) 2015-11-24
US9446136B2 (en) 2016-09-20
US7829118B1 (en) 2010-11-09
RU2539395C2 (ru) 2015-01-20
CL2012000243A1 (es) 2012-12-21
RU2012107283A (ru) 2013-09-10
US20170224708A1 (en) 2017-08-10
JP5683587B2 (ja) 2015-03-11
BR112012002117A2 (pt) 2019-09-24
CA2769470A1 (en) 2011-02-03
US8790702B2 (en) 2014-07-29
AU2010276574B2 (en) 2015-08-20
IL217750B (en) 2018-01-31
AU2010276574A1 (en) 2012-02-23
CN102573941A (zh) 2012-07-11
ZA201200727B (en) 2013-05-29
CN102573941B (zh) 2014-10-29
KR20120052371A (ko) 2012-05-23
US20120128741A1 (en) 2012-05-24
EP2459239A1 (en) 2012-06-06
MX2012001204A (es) 2012-08-03
US9980977B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
US9980977B2 (en) Modified hyaluronic acid polymer compositions and related methods
AU2012245517B2 (en) In-situ gel forming compositions
RU2486907C2 (ru) Имидированный биополимерный адгезив и гидрогель
JP6063867B2 (ja) ジスルフィド結合架橋生体適合性高分子ヒドロゲルおよびこれを含む製剤
ES2946738T3 (es) Sellante seco de acción rápida y métodos de uso y fabricación
KR20150104202A (ko) 히알루론산을 포함하는 안정화된 조성물
US20260042871A1 (en) Cholesterol-modified hyaluronic acids
HK1136973A (en) Polymer formulations for delivery of bioactive agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180904

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180904